Status: One Wales interim decision | |||
Using the agreed starting and stopping criteria, ustekinumab (Stelara®▼) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response, non-response or intolerance to anti-TNF therapies and vedolizumab; for Crohn’s disease following loss of response, non-response or intolerance to anti-TNF therapies. The risks and benefits of the off-label use of ustekinumab (Stelara®▼) for this indication should be clearly stated and discussed with the patient to allow informed consent. Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed. This advice will be reviewed after 12 months or earlier if new evidence becomes available. |
|||
|
|||
Medicine details |
|||
Medicine name | ustekinumab (Stelara®) | ||
Formulation | infusion | ||
Reference number | OW25 | ||
Indication | Treatment of inflammatory bowel disease in children and young people aged 6 to 17 years |
||
Company | Janssen-Cilag Ltd | ||
BNF chapter | Gastro-intestinal system | ||
Submission type | One Wales | ||
Status | One Wales interim decision | ||
Advice number | OW25 | ||
Date of issue | 02/03/2023 |